# An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

> **NCT02560649** · PHASE4 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 324 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Peginterferon alfa-2a plus Entecavir
- **DRUG:** Peginterferon alfa-2a plus Lamivudine
- **DRUG:** Peginterferon alfa-2a plus Adefovir
- **DRUG:** Peginterferon alfa-2a plus Tenofovir
- **DRUG:** Entecavir
- **DRUG:** Lamivudine
- **DRUG:** Adefovir
- **DRUG:** Tenofovir disoproxil

## Key facts

- **NCT ID:** NCT02560649
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2016-08
- **Final completion:** 2017-02
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2015-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560649, "An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02560649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*